Dr. Richard Carvajal, MD

Dr. Richard Carvajal, MD

Hematology  ·  
Male  ·  
45 y/o

Accepting new patients

Dr. Richard Carvajal, MD is a hematology specialist in New York, NY and has been practicing for 11 years. He specializes in hematology and medical oncology.Read his story

Columbia University Medical Center Division of Hematology/Oncology

161 Fort Washington Ave Fl 9

New York, NY 10032
Get Directions

Insurance Accepted

  • Aetna
  • Amalgamated Clothing & Textile Workers Union
  • Amerihealth
  • Blue Cross Blue Shield
  • Cigna
  • Commercial Insurance Company
  • EmblemHealth
  • Empire Blue Cross Blue Shield
  • Fidelis Care
  • Group Health Cooperative
  • Humana
  • Locals (any local)
  • MultiPlan

Learn about Dr. Carvajal

Be confident in your decisions by checking out your provider's top areas of care, education, patient reviews and more. Learn about finding the right doctor for you.

Top Care Areas

See how frequently Dr. Carvajal performs your care needs compared to other doctors.

more than 89% of peers
Secondary Malignancies
more than 73% of peers
Lung Cancer
more than 71% of peers

Dr. Carvajal's percentages are based on the rate of treatment compared to peers nationwide from insurance data. Learn more info about our data and this Top Care Areas component.

Dr. Carvajal's bio

This content was provided by Dr. Carvajal "As the Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, Dr. Carvajal is focused on the development of novel therapies for patients with melanoma and other cancers, with the overall objective of controlling and curing these diseases. To achieve this goal, he has used our increasing knowledge of the underlying biology of cancer to rapidly integrate this knowledge, novel therapeutic agents, and efficient trial design in order to improve the outcomes of cancer patients everywhere. Working closely with the laboratory scientists, the group is using the techniques of molecular biology to identify specific proteins, genes, or other molecules that influence the growth of each person's cancer, with the goal of selecting the most promising therapies for individual patients. Dr. Carvajal's melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as melanomas arising from the eye (uveal melanomas), from the mucosal surfaces of the body (mucosal melanomas), and from the palms of the hands, soles of the feet, or under the fingernails (acral melanomas). Although these tumors arise from pigment cells of the body just as do the more common melanomas that arise from the skin (cutaneous melanomas), they are clinically and biologically distinct from cutaneous disease. Once metastatic (that is, spread from where it originally began to other sites in the body), these diseases have proven to be difficult to treat. In an advance that helped to launch a new era of personalized medicine in melanoma therapy, Dr. Carvajal has led a clinical trial of imatinib (Gleevec) in patients with melanoma characterized by the presence of a mutation in a gene called KIT. While this mutation is rare in cutaneous melanoma, it is found in about 20% of mucosal and acral melanomas. Based in part on the positive results of this trial, where long-lasting tumor responses were observed in patients with these diseases, the use of imatinib in melanomas harboring KIT mutations was added to the National Comprehensive Cancer Network guidelines for the treatment of melanoma. Uveal melanoma is characterized by mutations in genes called GNAQ and GNA11 that lead to activation of a growth pathway called the MAPK pathway. Before 2013, there were no effective treatments for metastatic disease; however, another trial that Dr. Carvajal has developed and conducted identified selumetinib, a medicine that blocks the MAPK pathway, as the first effective treatment for patients with advanced uveal melanoma. Dr. Carvajal's research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation, the Empire Clinical Research Investigator Program, and the generous philanthropic support of our patients and their families. He has authored or co- authored more than 50 peer-reviewed manuscripts, books, and book chapters. In addition to Dr. Carvajal's work at Columbia University Medical Center, he serves as the co-chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research UK to enhance international collaboration in the conduct of clinical trials for uveal melanoma."


Read Less

Care Philosophy

This content was provided by Dr. Carvajal "We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person. "

2  Specialties

  • Hematology
  • Medical Oncology

2  Board Certifications

  • Hematology
    Accredited by: American Board of Internal Medicine*
  • Medical Oncology
    Accredited by: American Board of Internal Medicine*

98  Conditions Treated


Read Less

4  Procedures

Background Check

0 Malpractice Claims

No malpractice history found for New York.

0 Sanctions

No sanctions history found for the years that Healthgrades collects data.

0 Board Actions

No board actions found for the years that Healthgrades collects data.


  • New York University School of Medicine
    Medical School | Graduated 2000
  • University of Michigan Hospitals
    Residency Hospital | Completed 2003
  • Memorial Sloan Kettering
    Fellowship Hospital | Completed 2007

Awards & Recognition

Awards & Honors
  • Healthgrades Honor Roll
Media & Publications

Dr. Carvajal has no media or publications listed.

Languages Spoken

  • English

Memberships & Professional Affiliations

Dr. Carvajal does not have any memberships or affiliations listed. If you are Dr. Carvajal and would like to add memberships or affiliations, please update your profile.

Dr. Carvajal's Reviews

Likelihood of recommending Dr. Carvajal to family and friends
9 total reviews

Likelihood to Recommend (9)

  • 5
  • 4
  • 3
  • 2
  • 1

Dr. Carvajal's Performance

  • Trustworthiness

  • Explains condition(s) well

  • Answers questions

  • Time well spent


Office & Staff Performance

  • Scheduling

  • Office environment

  • Staff friendliness

  • Average wait time

    31 to 45 minutes
Are you Dr. Carvajal?
Make it easy for patients to share their feedback. Also manage your personalized profile!

More Hematology Specialists like Dr. Carvajal at Columbia University Medical Center Division of Hematology/Oncology

Hematology Specialist
Hematology Specialist
Hematology Specialist
Hematology Specialist
Medical Oncology Specialist
Medical Oncology Specialist